Fragment 176-191 + CJC-1295 + Ipamorelin

What Is the Fragment 176-191 + CJC-1295 + Ipamorelin Blend?

The Fragment 176-191 + CJC-1295 + Ipamorelin blend is a supplier-defined, three-peptide formulation that combines a C-terminal fragment of human growth hormone with two growth hormone secretagogues: CJC-1295 without DAC (Mod GRF 1-29) and ipamorelin. It is commonly listed as a 12 mg vial by total content, and the listings tracked here do not state a standard split among the three peptides.

HGH Fragment 176-191 reproduces residues 176-191 of human growth hormone; synthetic C-terminal hGH peptides including this sequence were tested in rats as early as 1978^[1]. CJC-1295 without DAC is a GHRH analogue, and ipamorelin is a pentapeptide described as the first selective growth hormone secretagogue^[2].

The blend name says only “CJC-1295”. In this catalog it refers to the form without DAC; CJC-1295 with DAC is a distinct molecule carrying an albumin-binding lysine extension^[3]. The combination is not an approved or standardized product.

Components at a Glance

Two components act on pituitary receptors that control growth hormone release; the third is a growth hormone fragment studied for metabolic effects rather than GH release.

Molecular weights are PubChem values (CIDs 16131230, 56841945 and 9831659).

Why These Compounds Are Studied Together

CJC-1295 and ipamorelin act on two different receptors in the growth hormone axis, while Fragment 176-191 is studied for a separate, metabolic line of research. No study of this three-peptide combination was found, and no cited source tests the fragment alongside either secretagogue.

The secretagogue pair

Ipamorelin releases GH through a GHRP-like receptor rather than the GHRH receptor, as shown by profiling with GHRP and GHRH antagonists^[2]. In rats treated with ipamorelin for 15 days, the pituitary GH response to GHRH was unchanged^[6]. A 2026 review reported that CJC-1295 combined with ipamorelin improved maximum tetanic tension in a mouse model of glucocorticoid-induced muscle loss, limited to animal work; the abstract does not state which CJC-1295 form was used^[7].

The fragment

The C-terminal hGH domain has been studied for direct effects on fat tissue. The closely related 177-191 analog AOD-9401 stimulated hormone-sensitive lipase and inhibited acetyl-CoA carboxylase in isolated rat adipose tissue, and reduced body weight gain in obese Zucker rats without inducing insulin resistance^[4]. In normal rats, however, the 176-191 sequence itself produced a short-lived rise in blood glucose and a more sustained rise in plasma insulin^[1]. These data come from rodents and concern the fragment alone.

Why they appear together

The grouping reflects how these peptides are marketed more than any tested rationale. A 2026 review lists Frag 176-191, ipamorelin and CJC-1295 among peptides promoted for muscle growth and fat metabolism, and notes that most published studies do not examine the combined protocols common in bodybuilding^[8].

With three peptides and easily confused fragment names, researchers typically check HPLC and mass spectrometry certificates of analysis that confirm each sequence.

Research Status

The Fragment 176-191 + CJC-1295 + Ipamorelin blend has no regulatory approval and is supplied for laboratory research use only. None of its three components is FDA approved, and a 2026 review notes the absence of regulatory approval for physique- or performance-related uses of GH-axis peptides^[9].

hGH 176-191 is among the prohibited peptides targeted by a 2026 doping-control detection workflow^[10]. Forensic analyses of seized material have identified glycine-modified analogues of ipamorelin and modified GRF 1-29^[11], and unregulated peptide products are often mislabeled or contaminated^[8]. Naming adds confusion: the review cited above refers to the GH fragment as “AOD9604 (hGH 176-191)”, although AOD-9604 is a modified 177-191 sequence^[9].

Evidence quality is low: rodent and in vitro data for the fragment, mainly animal data for ipamorelin, limited peer-reviewed data for CJC-1295 without DAC, and no published data on the combination.